LGD‑4033 (Ligandrol)
Experimental muscle-building SARM compound: muscle mass rose in small studies, but cases of liver injury are known; banned in sport.


The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

Related comparisons
LGD-4033 vs S23 vs S4DETAILED OVERVIEW
What is LGD-4033 (Ligandrol)?
LGD-4033 (Ligandrol) is an experimental compound from the group called SARMs (selective androgen receptor modulators): it imitates the muscle-building effect of testosterone but is not a steroid. It was developed by Ligand Pharmaceuticals but has never been approved as a medicine; it is sold as a research chemical.
Only a few small studies have been done in humans so far. In them, muscle mass rose, but the body's own testosterone production fell and liver enzymes rose moderately. Later, at least 12 cases of drug-induced liver injury were reported, some with jaundice and, in one case taken together with another SARM, sudden severe liver failure. The level of the good cholesterol (HDL) also fell markedly, and fertility worsens temporarily, with recovery taking months. It must not be used in pregnancy, because it may harm the baby's development. WADA has banned it year-round since 2008.
Mechanism
Non-steroidal selective AR modulator (pyrrolidinecarboxamide). Strong AR agonist in muscle, moderate prostate activity.
Anabolic activity (Basaria 2013)
In healthy men, lean body mass rose by about 1.2 kg
Half-life
~24-36 h (oral)
Onset
1-2 weeks (anecdotal strength gain)
Legal status
Never an Rx. UGL 'research chemical'. WADA-banned S1.2 since 2008.
No anecdote collected yet.
Data console
Lab data
Basaria S, Collins L, Dillon EL, Orwoll K, Storer TW, Miciek R, Ulloor J, Zhang A, Eder R, Zientek H, Gordon G, Kazmi S, Sheffield-Moore M, Bhasin S . The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men.. J Gerontol A Biol Sci Med Sci.
Leciejewska N, Jędrejko K, Gómez-Renaud VM, Manríquez-Núñez J, Muszyńska B, Pokrywka A . Selective androgen receptor modulator use and related adverse events including drug-induced liver injury: Analysis of suspected cases.. Eur J Clin Pharmacol.
Labban H, Kwait B, Paracha A, Khan A, Singh M, Lopez R . LGD-4033 and a Case of Drug-Induced Liver Injury: Exploring the Clinical Implications of Off-Label Selective Androgen Receptor Modulator Use in Healthy Adults.. Cureus.
Mohamed WT, Jahagirdar V, Fatima I, Ahmed MK, Goyal A, Sodeman T, Anwar N . Selective Androgen Receptor Modulators (SARMs)-Induced Liver Injury: A Case Report and Review of Literature.. Cureus.
Nash E, Nicoll A, Batt N, Iser D, Sood S . Drug-induced liver injury from selective androgen receptor modulators, anabolic-androgenic steroids and bodybuilding supplements in Australia.. Intern Med J.
Safety
Side effects, stop signs, contraindications
Side effects · 6
- Liver injury (drug-induced liver injury, DILI): 12+ documented hepatocellular injury case reports, some with jaundice and ALT >10x upper normal, fulminant course when stacked.
- HPTA suppression: dose-dependent drop in testosterone, LH and FSH (in the Basaria trial at 1 mg/day Total T -23%, LH -47%, FSH -42%); full suppression at higher UGL doses, PCT required.
- Lipid profile worsening: marked decrease in HDL cholesterol (approx. 30-40%), unfavorable cardiovascular risk with prolonged use.
- Reduced fertility: HPTA suppression can cause transient impaired spermatogenesis and lowered libido; full recovery may take 3-6 months.
- Mild androgenic effects: possible acne, oily skin and mood changes; in women at higher doses risk of virilization (voice deepening, hirsutism).
- Headache, fatigue and a sense of water retention at UGL doses (anecdotal), although LGD-4033 does not aromatize so true estrogen-driven edema is not typical.
Contraindications · 7
- Pre-existing liver dysfunction or elevated baseline ALT/AST: absolute contraindication due to documented DILI risk.
- Concurrent alcohol use or other hepatotoxic agents (other oral SARMs, 17-alpha-alkylated steroids): cumulative liver injury.
- Pregnancy and breastfeeding: androgen receptor activation can cause fetal virilization and developmental harm, use is prohibited.
- Planned fatherhood or active fertility goals in the near term: HPTA suppression is transient but with a 3-6 month recovery.
- Competitive sport under testing: WADA-banned since 2008 (S1.2), detectable in urine for 2-4 weeks, leads to doping sanctions.
- Diagnosed dyslipidemia or existing cardiovascular disease: the HDL decrease further worsens the risk profile.
- Anticoagulant (warfarin) therapy: mild anticoagulant potentiation, avoid without increased INR monitoring.
Related Performance Compounds
Same therapeutic category
Studies
Related research and clinical findings
The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men.
Basaria S, Collins L, Dillon EL, Orwoll K, Storer TW, Miciek R, Ulloor J, Zhang A, Eder R, Zientek H, Gordon G, Kazmi S, Sheffield-Moore M, Bhasin S
Selective androgen receptor modulator use and related adverse events including drug-induced liver injury: Analysis of suspected cases.
Leciejewska N, Jędrejko K, Gómez-Renaud VM, Manríquez-Núñez J, Muszyńska B, Pokrywka A
LGD-4033 and a Case of Drug-Induced Liver Injury: Exploring the Clinical Implications of Off-Label Selective Androgen Receptor Modulator Use in Healthy Adults.
Labban H, Kwait B, Paracha A, Khan A, Singh M, Lopez R
Selective Androgen Receptor Modulators (SARMs)-Induced Liver Injury: A Case Report and Review of Literature.
Mohamed WT, Jahagirdar V, Fatima I, Ahmed MK, Goyal A, Sodeman T, Anwar N
Drug-induced liver injury from selective androgen receptor modulators, anabolic-androgenic steroids and bodybuilding supplements in Australia.
Nash E, Nicoll A, Batt N, Iser D, Sood S
Telegram
Have a question about LGD‑4033 (Ligandrol)?
Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.